Qyuns Therapeutics (02509) Announces Share Repurchase and Adjusted Issued Shares

Qyuns Therapeutics (02509) disclosed that as of 19 November 2025, its issued share capital (excluding treasury shares) stood at 226,289,000 shares, alongside 782,600 treasury shares, totaling 227,071,600 shares. On 20 November 2025, 46,800 shares (about 0.0207% of the existing issued shares) were repurchased at an approximate average price of HKD 21.3213. Consequently, the closing balance reached 226,242,200 issued shares and 829,400 treasury shares, with the total remaining at 227,071,600 shares.

On the same date, a detailed repurchase report showed that the 46,800 shares were acquired on the Hong Kong Stock Exchange at prices ranging from HKD 21.00 to HKD 21.50, for an aggregate consideration of HKD 997,836.84. These repurchased shares will be held as treasury shares, and there is a stated moratorium period for issuing new shares or transferring treasury shares extending until 20 December 2025. The current repurchases fall under the company’s repurchase mandate of 22,207,160 shares, granted by resolution on 20 June 2025. As of the announcement date, 829,400 shares had been repurchased overall under this mandate, representing about 0.3735% of the issuer’s total shares (excluding treasury shares) when the mandate was approved.